<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785196</url>
  </required_header>
  <id_info>
    <org_study_id>APG115XC102</org_study_id>
    <nct_id>NCT04785196</nct_id>
  </id_info>
  <brief_title>APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ib/II Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Yasheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a phase Ib standard &quot;3 + 3&quot; design, will be employed to determine the MTD of&#xD;
      APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in&#xD;
      advanced solid tumors.&#xD;
&#xD;
      Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with&#xD;
      toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the&#xD;
      combination until disease progression, unacceptable toxicity, or another discontinuation&#xD;
      criterion is met.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is the open label, dose-escalation phase Ib portion of the study to establish an&#xD;
      MTD/RP2D of APG-115 in combination with toripalimab. Dose levels/schedule of APG115 will be&#xD;
      tested: 50mg, 100mg, 150mg, and 200mg, QOD with 2 weeks on 1 week off as a cycle of 21 days&#xD;
      (3 weeks), toripalimab will administrated with label dose.&#xD;
&#xD;
      Part 2 is the phase II portion of the study to evaluate the clinical efficacy and safety of&#xD;
      the RP2D of APG-115 in combination with label dose of toripalimab in patients with advanced&#xD;
      liposarcoma. In this part, Simon's two-stage design (Simon R (1989). Controlled Clinical&#xD;
      Trials 10: 1-10.) will be used. The null hypothesis that the true response rate of&#xD;
      combination is 30% or lower will be tested against a one-sided alternative. In the first&#xD;
      stage, 19 patients will be accrued. If there are 3 or fewer responses in these patients, the&#xD;
      study will be stopped. Otherwise, 15 additional patients will be accrued for a total of 34.&#xD;
      The null hypothesis will be rejected if 7 or more responses are observed in 34 patients. This&#xD;
      design yields a type I error rate of 0.05 and power of 90%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (Phase I)</measure>
    <time_frame>21 days</time_frame>
    <description>DLT will be defined based on the rate of drug-related grade 3-5 adverse events experienced within the first 3 weeks of study treatment. These will be assessed via CTCAE version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose</measure>
    <time_frame>21 days</time_frame>
    <description>Phase I is aimed to generate data to select the recommended Phase II dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (Phase II)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Phase II is to assess overall response rate of APG-115 in combination with toripalimab defined as the percentage of subjects with a best overall confirmed CR or a PR at any time as per RECIST v1.1.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Liposarcoma</condition>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>APG-115+Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-115</intervention_name>
    <description>Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.</description>
    <arm_group_label>APG-115+Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.</description>
    <arm_group_label>APG-115+Toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant, non-lactating female patients age ≥18 years on day of signing&#xD;
             the informed consent;&#xD;
&#xD;
          2. ECOG PS 0-1;&#xD;
&#xD;
          3. Phase Ib: Histologically confirmed, advanced liposarcoma or advanced solid tumor&#xD;
             patients who failed standard of care therapy; Phase II: Histologically confirmed,&#xD;
             advanced liposarcoma with TP53 wide-type and MDM2 Amplification;&#xD;
&#xD;
          4. The expected survival period is more than 12 weeks;&#xD;
&#xD;
          5. Measurable disease on CT or MRI by RECIST 1.1.&#xD;
&#xD;
          6. Adequate bone marrow and organ function as indicated by: the following laboratory&#xD;
             values without continuous supportive treatment (such as blood transfusion, coagulation&#xD;
             factors and/or platelet infusion, red/white blood cell growth factor administration,&#xD;
             or albumin infusion)&#xD;
&#xD;
               1. ANC≥1.5 x 10^9/ L;&#xD;
&#xD;
               2. PLT≥100 x 10^9/ L;&#xD;
&#xD;
               3. Hgb≥90 g/L;&#xD;
&#xD;
               4. Alb≥30 g/L;&#xD;
&#xD;
               5. AST and AST ≤3 * ULN (for hepatic metastases, ALT and AST≤5*ULN);&#xD;
&#xD;
               6. Serum creatinine (Cr) ≤ 1.5ULN or creatinine clearance (CCr) ≥ 50ml / min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have previously been treated with MDM2-p53 inhibitor;&#xD;
&#xD;
          2. Known hypersensitivity reaction to PD-(L)1 inhibitors, or any prior ≥ Grade 3 irAE;&#xD;
&#xD;
          3. Prior treatment consisted of any kinds of immunotherapies, like PD-(L)1 inhibitors,&#xD;
             anti-PD-L2 antibodies, CTLA-4, OX-40 et.al( for phase II);&#xD;
&#xD;
          4. Has known active central nervous (CNS) metastases and/or carcinomatous meningitis;&#xD;
&#xD;
          5. Has any active or history of autoimmune disease;&#xD;
&#xD;
          6. Active infection or unexplained fever &gt; 38.5 ° C two weeks before first dose;&#xD;
&#xD;
          7. Patients with any severe and/or uncontrolled diseases, including: hypertension and&#xD;
             uncontrollable levels of normal anti-hypertensive medication; clinically significant&#xD;
             cardiovascular and cerebrovascular diseases, including but not limited to severe acute&#xD;
             myocardial infarction, unstable or severe angina, or coronary artery bypass surgery,&#xD;
             congestive heart failure (New York Heart Association (NYHA) ) &gt; 2);active or&#xD;
             uncontrolled serious infection (≥CTCAE 5.0 Level 2 infection);objective evidence of&#xD;
             previous or current history of pulmonary disease; moderate to severe hepatic&#xD;
             impairment (Child-Pugh score ≥ 10 points); moderate to severe renal impairment or&#xD;
             psychiatric illness/social circumstances that may affect study compliance;&#xD;
&#xD;
          8. Poorly controlled arrhythmia (including QTc interval ≥450 ms for males and ≥470 ms for&#xD;
             females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Guo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yifan Zhai, MD, PhD</last_name>
    <phone>+86-20-28068501</phone>
    <email>Yzhai@ascentage.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guojuan Chen, MD.</last_name>
    <phone>+86-20-28068520</phone>
    <email>guojuan.chen@ascentage.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xing Zhang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital (East Hospital affiliated to Tongji University)</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Guo, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APG-115</keyword>
  <keyword>Toripalimab</keyword>
  <keyword>Liposarcoma</keyword>
  <keyword>Advanced solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

